Universal Ibogaine — Fact Sheet (November 2021)

3 slides from Universal Ibogaine's fact sheet, November 2021

Slide 1: Ibogaine Fact Sheet
(UN) UNIVERSAL tii IBOGAINE IBOGAINE FACT SHEET GLOBAL EPIDEMIC Opioid use disorder involving prescription and non-prescription opioids has become a widespread devastating global epidemic. Opioid use disorder is notoriously difficult to treat. Withdrawal from opioids can be physically and psychologi
Slide 2: Development Timeline
DEVELOPMENT TIMELINE Ibogaine found its first medical application as a neuromuscular stimulant. Sold in France under the trade name Lambaréne, these 8-mg ibogaine tablets were prescribed for recovery from infectious disease, fatigue, and depression 1966 Almost 30 years later, the product was removed
Slide 3: Development Timeline and Legal Status
DEVELOPMENT TIMELINE 2017 Health Canada placed ibogaine on the Prescription Drug after reports of adverse events from an unauthorized health product called Remogen. The addition of ibogaine to the PDL would allow Health Canada to provide more effective risk-based oversight of ibogaine: by requiring